OmniTier’s Genomic Analysis Platform Improved Diagnostics Rate for Rare Diseases
The NCCHD in Japan and OmniTier detailed how the company’s genomic analysis platform improved diagnostic rates for rare diseases.
Read MorePosted by Andy Lundin | Feb 3, 2023 | Disease States |
The NCCHD in Japan and OmniTier detailed how the company’s genomic analysis platform improved diagnostic rates for rare diseases.
Read MorePosted by Andy Lundin | Feb 2, 2023 | Prostate |
Investigators found that the test was able to distinguish cancer localized to the prostate from cancer that spread to other parts of the body.
Read MorePosted by Andy Lundin | Jan 26, 2023 | Unknown Origin & Other Cancer Types |
Population-based genomic screening facilitates early detection of medullary thyroid cancer (MTC) in patients with variants in the RET gene.
Read MorePosted by Andy Lundin | Jan 24, 2023 | Lung Cancer |
Thermo Fisher Scientific is working with AstraZeneca to develop a solid tissue and blood-based companion diagnostic test for Tagrisso.
Read MorePosted by Andy Lundin | Jan 24, 2023 | Diagnostic Technologies |
NanoMosaic established a scientific advisory board to help bring nanoneedle-powered digital proteomic tools to the diagnostic community.
Read More